Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM-Reference-Cited by-同舟云学术

Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM

Published:2013-10-31 Issue:4 Volume:16 Page:351-356
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Jacober S. J.¹,Rosenstock J.²,Bergenstal R. M.³,Prince M. J.¹,Qu Y.¹,Beals J. M.¹

Affiliation:

1. Eli Lilly and Company; Indianapolis IN USA

2. Dallas Diabetes and Endocrine Center at Medical City; Dallas TX USA

3. International Diabetes Center at Park Nicollet; Minneapolis MN USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12223/fullpdf

Reference15 articles.

1. Insulin-associated weight gain in diabetes-causes, effects and coping strategies;Russell-Jones;Diabetes Obes Metab,2007

2. Body weight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus;Hermansen;Drug Saf,2007

3. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?;Hermansen;Diabetes Obes Metab,2007

4. Differences between long-acting insulins for the treatment of type 2 diabetes;Jensen;Expert Opin Pharmacother,2010

5. Insulin detemir versus insulin glargine for type 2 diabetes mellitus;Swinnen;Cochrane Database Syst Rev,2011

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus;Diabetes, Obesity and Metabolism;2018-05

2. Characterisation of insulin analogues therapeutically available to patients;PLOS ONE;2018-03-29

3. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes;Diabetes, Obesity and Metabolism;2017-10-10

4. Glargine and degludec: Solution behaviour of higher dose synthetic insulins;Scientific Reports;2017-08-04

5. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion;Diabetes Technology & Therapeutics;2017-05